What’s New With NASH?
September 14, 2023 2:30pm – 4:00pm (ET) Online
CE: Pending approval for 1.25 contact hours
Includes 0.25 hours of pharmacology
What's new with nonalcoholic steatohepatitis (NASH)? So much! Join nurse practitioner (NP) experts Drs. Kelly Casler and Amanda Chaney in this live webinar, as they discuss screening, diagnosis, management and emerging therapies and bring you up to date with the new nomenclature for steatotic liver disease. You will have the opportunity to participate in a live Q&A session with these experts following the webinar broadcast. The recording of the webinar will be made available as an on-demand presentation within a week of the live event.
-
Webinar Details
When: Sept. 14, 2023, 2:30-4 p.m. ET (1:30-3 p.m. CT).
Where: Online, via the AANP CE Center.
Cost: Free for AANP members and non-members.
CE Credit: This activity is pending approval by the American Association of Nurse Practitioners® (AANP) for 1.25 contact hours (CH) of continuing education (CE) credit, including 0.25 CH of pharmacology credit. This activity was planned in accordance with AANP Accreditation Standards and Policies.
About the Webinar
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and affects an estimated 25% of the adult population in the U.S. About one-quarter of patients with NAFLD have NASH. NPs are key providers for this population. Stay abreast of best practices for the screening, diagnosis and treatment of these conditions with insights from this free AANP webinar. NP experts Drs. Kelly Casler and Amanda Chaney will share details about exciting, emerging treatment options and discuss new nomenclature.
Objectives:
- Identify patients who are candidates for NAFLD screening based on established risk factors.
- Summarize strategies for the diagnosis and risk stratification of NASH.
- Choose evidence-based recommendations for managing NASH, using nonpharmacologic and pharmacologic approaches.
- Describe the mechanism of action, safety and efficacy of emerging liver-directed pharmacotherapies for the management of NASH.
This program is supported by independent medical educational grants from Madrigal Pharmaceuticals & Novo Nordisk Inc.
-
Speakers
Kelly Casler, DNP, APRN-CNP, CHSE, EBP-C, FAANP
Dr. Kelly Small Casler has been teaching in academia for over 12 years and is an associate clinical professor at The Ohio State University College of Nursing, where she teaches in the Family Nurse Practitioner (FNP) and Doctor of Nursing Practice (DNP) programs. Casler obtained her DNP degree in 2018 through the University of Kansas School of Nursing and completed both a BSN and MS in Nursing at the University of Missouri-Columbia. Her DNP project focus was on a toolkit to support primary care providers in delivering evidence-based practice for NAFLD, and she is currently expanding on that work by serving a two-year term as the only NP commissioner for the Liver Disease in Primary Care Commission for The Lancet: Gastroenterology and Hepatology. Casler launched her nursing career 22 years ago as a surgical/burn/trauma critical care nurse. The last 16 years of her nursing career have been spent as an FNP working in both urban and rural family practices in Missouri and Ohio. Most importantly, Casler is a proud Air Force spouse and a proud mom to Caleb and Zach.
Amanda Chaney, DNP, APRN, FAANP, AF-AASLD
Amanda Chaney is an NP and Senior Director of Advanced Practice Provider Services at Cleveland Clinic in Florida, staffing over 430 NPs and physician assistants (PAs). Prior to this role, Dr. Chaney served at Mayo Clinic for over 20 years in a variety of roles in leadership, patient care, and academic faculty. Dr. Chaney is a renowned speaker and has published over 20 peer-reviewed articles. She has been instrumental in national change for NP and PA practice, consulting with organizations across the nation. She was inducted as a Fellow of the American Association of Nurse Practitioners (FAANP) in 2017, State Award of Excellence for AANP in 2018, and Associate Fellow of the American Association for the Study of Liver Disease (AF-AASLD) in 2020. Dr. Chaney was a featured guest on Becker’s Healthcare podcast in 2020.